Grifols, SA
GRFS
ISIN null / Valor 19108728
Grifols, SA
UMushroom community rating:
About company
Grifols, SA is a global healthcare company that specializes in the development, production, and distribution of plasma-derived medicines, other biopharmaceuticals, and transfusion medicine solutions. The company plays a critical role in the healthcare sector by providing essential products that support the treatment of rare and chronic conditions. Grifols' offerings include innovative technologies and products for blood typing, specifically the agglutination technique that uses gel in columns for determining blood groups and ensuring transfusion compatibility. Additionally, the company is involved in the production of organic compounds, including amino acids that are vital for various bodily functions and medical treatments. Grifols' commitment to healthcare innovation extends to the preparation of medicines for intravenous use, which can be prepared through reconstitution or by mixing with existing solutions for fluid therapy. With a focus on improving patient outcomes, Grifols continues to be a key player in the healthcare industry, enabling millions of patients worldwide to lead more productive lives through its trusted and innovative solutions.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (11.10.2025):
Grifols, SA reported strong financial performance in Q1 2025, showcasing significant growth in revenues, adjusted EBITDA, and free cash flow. The company reaffirmed its guidance for the full year 2025, indicating continued momentum and consistent growth ahead.
Revenue Growth
In the first quarter of 2025, Grifols achieved a 7.4% constant currency increase in revenues, reaching EUR 1,786 million. This growth reflects the company's robust market position and effective execution of its strategic initiatives.
Adjusted EBITDA Improvement
Adjusted EBITDA saw a substantial rise of 14.2% constant currency, totaling EUR 400 million in Q1 2025. This improvement underscores Grifols' operational efficiency and ability to enhance profitability.
Enhanced Free Cash Flow
Free cash flow for the quarter increased by EUR 209 million compared to the same period last year, highlighting Grifols' strong cash generation capabilities and financial health.
Positive Outlook for 2025
Grifols reaffirmed its guidance for the full year 2025, emphasizing sustained growth and continued focus on executing its strategic plan to serve patients, donors, and customers effectively.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
2195 M
Market cap (USD)
710,442
Daily traded volume (Shares)
7.49 / 7.3
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
